160 related articles for article (PubMed ID: 33586456)
1. Influence of
Zhang X; Liu C; Zhou S; Xie R; He X; Wang Z; Yi H; Shu Y; Wang Z; Hu K; Ma L; Cui Y; Zhao X; Xiang J
Pharmacogenomics; 2021 Mar; 22(4):213-223. PubMed ID: 33586456
[No Abstract] [Full Text] [Related]
2. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
3. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
4. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
5. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
Koller D; Belmonte C; Lubomirov R; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Carcas A; Wojnicz A; Abad-Santos F
J Psychopharmacol; 2018 Nov; 32(11):1212-1222. PubMed ID: 30251598
[TBL] [Abstract][Full Text] [Related]
6. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
Kubo M; Koue T; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
9. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
10. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
11. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
Koller D; Belmonte C; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):236-246. PubMed ID: 31520576
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of aripiprazole in healthy Korean subjects.
Jeon JY; Chae SW; Kim MG
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):293-304. PubMed ID: 26902506
[TBL] [Abstract][Full Text] [Related]
14. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
Guo L; Wang S; Wan Z; Ni S; Xu B; Zhao X; Liu L
J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
[No Abstract] [Full Text] [Related]
20. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]